Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17034713 | 0.79 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL8820595 | 0.76 | GAA (0.50) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL6866745 | 0.76 | GAA (0.50) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL21052480 | 0.75 | GAA (0.55) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL232993 | 0.75 | GAA (0.55) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL798062 | 0.75 | GAA (0.55) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL927785 | 0.73 | GAA (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11861490 | 0.73 | GAA (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL7563037 | 0.73 | GAA (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL9610126 | 0.72 | GAA (0.41) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492170-B2 | Tetrahydro-1H-benzazepine compound as potassium channel modulator, preparation method and use thereof | SHANGHAI ZHIMENG BIOPHARMA, INC. (CN) | 2025-12-09 | — | — | US | disclosed |
| US-RE50453-E1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| EP-3978478-B1 | TETRAHYDRO-1H-BENZAZEPINE COMPOUND AS POTASSIUM CHANNEL MODULATOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2024-02-14 | — | — | EP | disclosed |
| US-11639347-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230100634-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-03-30 | — | — | US | disclosed |
| US-20220227713-A1 | TETRAHYDRO-1H-BENZAZEPINE COMPOUND AS POTASSIUM CHANNEL MODULATOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI ZHIMENG BIOPHARMA, INC. (CN) | 2022-07-21 | — | — | US | disclosed |
| EP-3978478-A1 | TETRAHYDRO-1H-BENZAZEPINE COMPOUND AS POTASSIUM CHANNEL MODULATOR, PREPARATION METHOD AND USE THEREOF | Shanghai Zhimeng Biopharma, Inc. (CN) | 2022-04-06 | — | — | EP | disclosed |
| CN-113767091-A | tetrahydro-1H-benzazepine compounds as potassium channel modulators, and preparation and application thereof | 上海挚盟医药科技有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-7645789-B2 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645789-B2 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645789-B2 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| WO-2007065661-A1 | BIPHENYL DERIVATIVES BEARING AN ACETYLENE GROUP AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-4276225-A | PHOSPHOLINE OXIDE OR PHOSPHETANE OXIDE SOLVENT | BAYER AKTIENGESELLSCHAFT (DE) | 1981-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492170-B2 | Tetrahydro-1H-benzazepine compound as potassium channel modulator, preparation method and use thereof | KCNB1, KCNJ2, KCNA1 | GAA 3484/4885MGAM 3241/4885SI 1765/4885 |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | CFTR, ABCB1, ABCB11 | GAA 1992/4885MGAM 2626/4885SI 1422/4885 |
| US-11639347-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | GAA 328/4885MGAM 2107/4885SI 1932/4885 |
| US-20220227713-A1 | TETRAHYDRO-1H-BENZAZEPINE COMPOUND AS POTASSIUM CHANNEL MODULATOR, PREPARATION METHOD AND USE THEREOF | KCNB1, KCNJ2, KCNA1 | GAA 3484/4885MGAM 3241/4885SI 1765/4885 |
| US-20230100634-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | GAA 328/4885MGAM 2107/4885SI 1932/4885 |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | GAA 328/4885MGAM 2107/4885SI 1932/4885 |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | CFTR, ABCD3, ABCC2 | GAA 3145/4885MGAM 3631/4885SI 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.